Suramin: a potential therapy for diabetic nephropathy.
To determine whether delayed administration of a single dose of suramin, a drug that has been used extensively in humans to treat trypanosomiasis, attenuates renal injury in a leptin receptor deficient C57BLKS/J db/db type 2 diabetic nephropathy (T2DN) mouse model.Groups of female non-diabetic (cont...
Main Authors: | , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2013-01-01
|
Series: | PLoS ONE |
Online Access: | http://europepmc.org/articles/PMC3767615?pdf=render |
id |
doaj-89bd3183f4a34945ade783ba141ee564 |
---|---|
record_format |
Article |
spelling |
doaj-89bd3183f4a34945ade783ba141ee5642020-11-25T01:51:08ZengPublic Library of Science (PLoS)PLoS ONE1932-62032013-01-0189e7365510.1371/journal.pone.0073655Suramin: a potential therapy for diabetic nephropathy.Midhun C KorrapatiLauren A HowellBrooke E ShanerJudit K MegyesiLeah J SiskindRick G SchnellmannTo determine whether delayed administration of a single dose of suramin, a drug that has been used extensively in humans to treat trypanosomiasis, attenuates renal injury in a leptin receptor deficient C57BLKS/J db/db type 2 diabetic nephropathy (T2DN) mouse model.Groups of female non-diabetic (control) db/m and diabetic db/db mice of 8 and 16 weeks of age, respectively, were treated with suramin (10 mg/kg) or saline i.v. All animals were euthanized one week later. Measurements in mice 1 week following treatment included the following: body weight; blood glucose; urinary protein excretion; pathological lesions in glomeruli and proximal tubules; changes in protein expression of pro-inflammatory transcription factor nuclear factor κB (NF-κB) and intracellular adhesion molecule-1 (ICAM-1), profibrotic transforming growth factor-β1 (TGF-β1), phospho-SMAD-3 and alpha-smooth muscle actin (α-SMA); and immunohistochemical analysis of leukocyte infiltration and collagen 1A2 (COL1A2) deposition.Immunoblot analysis revealed increased NF-κB, ICAM-1, TGF-β1, phospho-SMAD-3, and α-SMA proteins in both 9 and 17 week db/db mice as compared to db/m control mice. Immunohistochemical analysis revealed moderate leukocyte infiltration and collagen 1A2 (COL1A2) deposition in 9 week db/db mice that was increased in the 17 week db/db mice. Importantly, suramin significantly decreased expression of all these markers in 9 week db/db mice and partially decreased in 17 week db/db mice without altering body weight, blood glucose or urinary protein excretion. There was no difference in creatinine clearance between 9 week db/m and db/db mice ± suramin. Importantly, in the 17 week db/db mice suramin intervention reversed the impaired creatinine clearance and overt histological damage.Delayed administration of a single dose of suramin in a model of T2DN attenuated inflammation and fibrosis as well as improved renal function, supporting the use of suramin in T2DN.http://europepmc.org/articles/PMC3767615?pdf=render |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Midhun C Korrapati Lauren A Howell Brooke E Shaner Judit K Megyesi Leah J Siskind Rick G Schnellmann |
spellingShingle |
Midhun C Korrapati Lauren A Howell Brooke E Shaner Judit K Megyesi Leah J Siskind Rick G Schnellmann Suramin: a potential therapy for diabetic nephropathy. PLoS ONE |
author_facet |
Midhun C Korrapati Lauren A Howell Brooke E Shaner Judit K Megyesi Leah J Siskind Rick G Schnellmann |
author_sort |
Midhun C Korrapati |
title |
Suramin: a potential therapy for diabetic nephropathy. |
title_short |
Suramin: a potential therapy for diabetic nephropathy. |
title_full |
Suramin: a potential therapy for diabetic nephropathy. |
title_fullStr |
Suramin: a potential therapy for diabetic nephropathy. |
title_full_unstemmed |
Suramin: a potential therapy for diabetic nephropathy. |
title_sort |
suramin: a potential therapy for diabetic nephropathy. |
publisher |
Public Library of Science (PLoS) |
series |
PLoS ONE |
issn |
1932-6203 |
publishDate |
2013-01-01 |
description |
To determine whether delayed administration of a single dose of suramin, a drug that has been used extensively in humans to treat trypanosomiasis, attenuates renal injury in a leptin receptor deficient C57BLKS/J db/db type 2 diabetic nephropathy (T2DN) mouse model.Groups of female non-diabetic (control) db/m and diabetic db/db mice of 8 and 16 weeks of age, respectively, were treated with suramin (10 mg/kg) or saline i.v. All animals were euthanized one week later. Measurements in mice 1 week following treatment included the following: body weight; blood glucose; urinary protein excretion; pathological lesions in glomeruli and proximal tubules; changes in protein expression of pro-inflammatory transcription factor nuclear factor κB (NF-κB) and intracellular adhesion molecule-1 (ICAM-1), profibrotic transforming growth factor-β1 (TGF-β1), phospho-SMAD-3 and alpha-smooth muscle actin (α-SMA); and immunohistochemical analysis of leukocyte infiltration and collagen 1A2 (COL1A2) deposition.Immunoblot analysis revealed increased NF-κB, ICAM-1, TGF-β1, phospho-SMAD-3, and α-SMA proteins in both 9 and 17 week db/db mice as compared to db/m control mice. Immunohistochemical analysis revealed moderate leukocyte infiltration and collagen 1A2 (COL1A2) deposition in 9 week db/db mice that was increased in the 17 week db/db mice. Importantly, suramin significantly decreased expression of all these markers in 9 week db/db mice and partially decreased in 17 week db/db mice without altering body weight, blood glucose or urinary protein excretion. There was no difference in creatinine clearance between 9 week db/m and db/db mice ± suramin. Importantly, in the 17 week db/db mice suramin intervention reversed the impaired creatinine clearance and overt histological damage.Delayed administration of a single dose of suramin in a model of T2DN attenuated inflammation and fibrosis as well as improved renal function, supporting the use of suramin in T2DN. |
url |
http://europepmc.org/articles/PMC3767615?pdf=render |
work_keys_str_mv |
AT midhunckorrapati suraminapotentialtherapyfordiabeticnephropathy AT laurenahowell suraminapotentialtherapyfordiabeticnephropathy AT brookeeshaner suraminapotentialtherapyfordiabeticnephropathy AT juditkmegyesi suraminapotentialtherapyfordiabeticnephropathy AT leahjsiskind suraminapotentialtherapyfordiabeticnephropathy AT rickgschnellmann suraminapotentialtherapyfordiabeticnephropathy |
_version_ |
1724998292372193280 |